Blood lactate levels in patients receiving first- or second- generation antipsychotics

Trpimir Glavina, Damir Mrass, Tajana Dodig, Gordana Glavina, Shelly Pranić, Boran Uglešić, Trpimir Glavina, Damir Mrass, Tajana Dodig, Gordana Glavina, Shelly Pranić, Boran Uglešić

Abstract

Aim: To compare the blood lactate levels between patients with psychotic disorder receiving first- and those receiving second-generation antipsychotics.

Methods: The study was conducted at the psychiatric inpatient and outpatient clinics of the Split Clinical Hospital from June 6, 2008 to October 10, 2009. Sixty patients with psychotic disorder who were assigned to 6-month treatment were divided in two groups: 30 received haloperidol (first generation antipsychotic) and 30 received olanzapine (second generation antipsychotic). Blood lactate levels, other metabolic parameters, and scores on the extrapyramidal symptom rating scale were assessed.

Results: Patients receiving haloperidol had significantly higher blood lactate levels than patients receiving olanzapine (P < 0.001). They also more frequently had parkinsonism, which was significantly correlated with both haloperidol treatment at 1 month (P < 0.001) and 6 months (P = 0.016) and olanzapine treatment at baseline (P = 0.016), 3 months (P = 0.019), and 6 months (P = 0.021). Also, patients receiving haloperidol had significant correlation between blood lactate and dystonia at 1 month (P < 0.001) and 6 months (P = 0.012) and tardive dyskinesia at 1 month (P = 0.032). There was a significant difference between the treatment groups in lactate levels at all points from baseline to month 6 (P < 0.001).

Conclusion: It is important to be aware of the potential effect of haloperidol treatment on increase in blood lactate levels and occurrence of extrapyramidal side effects. Therefore, alternative antipsychotics should be prescribed with lower risk of adverse side effects.

Trial registration: ClinicalTrials.gov NCT01139463.

References

    1. Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry. 2000;61(Suppl 8):5–11.
    1. Marder SR. Newer antipsychotics. Curr Opin Psychiatry. 2000;13:11–4. doi: 10.1097/00001504-200001000-00003.
    1. Mackin P, Watkinson HM, Young AH. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia. 2005;48:215–21. doi: 10.1007/s00125-004-1641-y.
    1. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62:19–28. doi: 10.1001/archpsyc.62.1.19.
    1. Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes. 2005;54:862–71. doi: 10.2337/diabetes.54.3.862.
    1. Worrel JA, Marken PA, Beckman SE, Ruehter VL. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm. 2000;57:238–55.
    1. Stahl SM. Essential psychopharmacology. New York (NY): Cambridge University Press; 1996.
    1. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv. 1998;49:1163–72.
    1. Sachdev PS. The current status of tardive dyskinesia. Aust N Z J Psychiatry. 2000;34:355–69.
    1. Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q. 1992;63:51–70. doi: 10.1007/BF01064682.
    1. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361:1581–9. doi: 10.1016/S0140-6736(03)13306-5.
    1. Markianos M, Hatzimanolis J, Lykouras L. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. Eur Arch Psychiatry Clin Neurosci. 2001;251:141–6. doi: 10.1007/s004060170049.
    1. Nichol AD, Egi M, Pettila V, Bellomo R, French C, Hart G, et al. Relative hyperlactatemia and hospital mortality in critically ill patients: a retrospective multi-centre study. Crit Care. 2010;14:R25. doi: 10.1186/cc8888.
    1. Bakker J, de Lima AP. Increased blood lacate levels: an important warning signal in surgical practice. Crit Care. 2004;8:96–8. doi: 10.1186/cc2841.
    1. Adrogue HJ, Madias NE. Management of life-threatening acid-base disorders. First of two parts. N Engl J Med. 1998;338:26–34.
    1. De Backer D. Lactic acidosis. Intensive Care Med. 2003;29:699–702.
    1. Adrogue HJ, Madias NE. Management of life-threatening acid-base disorders. Second of two parts. N Engl J Med. 1998;338:107–11.
    1. Smith I, Kumar P, Molloy S, Rhodes A, Newman PJ, Grounds RM, et al. Base excess and lactate as prognostic indicators for patients admitted to intensive care. Intensive Care Med. 2001;27:74–83. doi: 10.1007/s001340051352.
    1. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry. 2001;62:15–26.
    1. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry. 1968;124:978–82.
    1. Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clin Pharmacol Ther. 1970;11:883–9.
    1. Amdisen A. Drug-produced obesity. Experiences with chlorpromazine, perphenazine and clopenthixol. Dan Med Bull. 1964;11:182–9.
    1. Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy. 2003;23:735–44. doi: 10.1592/phco.23.6.735.32178.
    1. Bustillo JR, Buchanan RW, Irish D, Breier A. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry. 1996;153:817–9.
    1. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1–93. doi: 10.2165/00023210-200519001-00001.
    1. Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry. 1998;59:294–9. doi: 10.4088/JCP.v59n0604.
    1. McCracken M, Ainsworth B, Hackney AC. Effects of the menstrual cycle phase on the blood lactate responses to exercise. Eur J Appl Physiol Occup Physiol. 1994;69:174–5. doi: 10.1007/BF00609412.
    1. Stephenson LA, Kolka MA, Wilkerson JE. Metabolic and thermoregulatory responses to exercise during the human menstrual cycle. Med Sci Sports Exerc. 1982;14:270–5. doi: 10.1249/00005768-198204000-00003.
    1. Sutton JR, Jurkowski JE, Keane P, Walker WHC, Jones NL, Toews CJ. Plasma-catecholamine, insulin, glucose and lactate responses to exercise in relation to the menstrual-cycle. Med Sci Sports. 1980;12:83–4.
    1. Jurkowski JE, Jones NL, Toews CJ, Sutton JR. Effects of menstrual cycle on blood lactate, O2 delivery, and performance during exercise. J Appl Physiol. 1981;51:1493–9.
    1. Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, et al. Metformin addition attenuates olanzapine induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry. 2008;165:352–8. doi: 10.1176/appi.ajp.2007.07010079.
    1. Baldwin DS, Montgomery SA. First clinical experience with olanzapine (LY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia. Int Clin Psychopharmacol. 1995;10:239–44. doi: 10.1097/00004850-199511000-00005.
    1. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005;76:247–65. doi: 10.1016/j.schres.2005.02.013.
    1. Uribarri J, Oh MS, Carroll HJ. D-lactic acidosis. A review of clinical presentation, biochemical features, and pathophysiologic mechanisms. Medicine. 1998;77:73–82. doi: 10.1097/00005792-199803000-00001.
    1. Tello R, Crewson PE. Hypothesis testing II: means. Radiology. 2003;227:1–4. doi: 10.1148/radiol.2271020085.
    1. Rollema H, Skolnik M, D'Engelbronner J, Igarashi K, Usuki E, Castagnoli N., Jr MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J Pharmacol Exp Ther. 1994;268:380–7.
    1. Kliegel A, Losert H, Sterz F, Holzer M, Zeiner A, Havel C, et al. Serial lactate determinations for prediction of outcome after cardiac arrest. Medicine. 2004;83:274–9. doi: 10.1097/01.md.0000141098.46118.4c.
    1. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;160:1396–404. doi: 10.1176/appi.ajp.160.8.1396.
    1. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003;60:1218–26. doi: 10.1001/archpsyc.60.12.1218.
    1. Devanand DP, Pelton GH, Cunqueiro K, Sackeim HA, Marder K.A 6-month randomized, randomized double-blind, placebo-controlled discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer’s disease Int J Geriatr Psychiatry 2010. Dec 28. [Epub ahead of print]10.1002/gps.2630
    1. Bobo WV, Jayathilake K, Lee MA, Meltzer HY. Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics. Hum Psychopharmacol. 2009;24:415–22. doi: 10.1002/hup.1036.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner